PMID- 21674024
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 4
DP  - 2011
TI  - Intravenous moxifloxacin in routine hospital treatment of respiratory tract 
      infections in China: results of a multicenter, noninterventional study.
PG  - 317-23
LID - 10.2147/IJGM.S14537 [doi]
AB  - OBJECTIVE: To investigate the effectiveness, safety, and tolerability of 
      moxifloxacin (MXF) (intravenous [IV] or sequential therapy [IV followed by oral]) 
      under daily treatment conditions in a large number of patients with respiratory 
      tract infections. DESIGN: Patients with a diagnosis of respiratory tract 
      infection should be treated with MXF IV and/or tablets 400 mg once daily for a 
      duration at the physician's discretion. For each patient, the physician 
      documented data at an initial visit and at the end of therapy (EOT) visit and/or, 
      in the case of sequential therapy, an interim visit when the patient switched to 
      oral treatment. RESULTS: A total of 1953 patients treated with MXF were 
      documented and were valid for an effectiveness and safety evaluation. An 
      improvement was observed in 98.1% (n = 1911/1949) of patients treated with MXF. 
      Recovery was documented in 89.9% (n = 1754/1951) of the patients. At the EOT 
      visit, severity of infection was assessed to be "relieved" or at least "improved" 
      in 96.5% (n = 1873/1940) of the patients. Physicians assessed overall 
      effectiveness as "good" or "very good" in 93.3% (n = 1822/1953) of all patients. 
      The physicians' overall tolerability rating was "very good" or "good" in 93.5% (n 
      = 1827/1953) of all patients. The incidence rates of adverse events (AEs) and 
      adverse drug reactions (ADRs) were 0.72% (n = 14) and 0.67% (n = 13), 
      respectively. One serious AE "falling white blood cell count" occurred (0.05%), 
      which was also defined as a serious ADR and resolved. CONCLUSION: MXF was 
      generally well tolerated and highly effective in the treatment of different 
      respiratory tract infections. The incidence of AEs and ADRs was low. The 
      efficacy, safety, and tolerability information collected in this study confirms 
      the clinical safety profile of MXF and its value as antibiotic treatment for 
      respiratory tract infections.
FAU - Chen, Rongchang
AU  - Chen R
AD  - State Key Laboratory of Respiratory Disease, First Affiliated Hospital of 
      Guangzhou Medical University, China;
FAU - Ma, Wenjiang
AU  - Ma W
FAU - Yu, Xuezhong
AU  - Yu X
FAU - Liu, Xinmin
AU  - Liu X
FAU - Zhu, Jihong
AU  - Zhu J
FAU - Liang, Hong
AU  - Liang H
FAU - Wu, Xiaomei
AU  - Wu X
FAU - Guo, Tao
AU  - Guo T
LA  - eng
PT  - Journal Article
DEP - 20110418
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC3108199
OTO - NOTNLM
OT  - moxifloxacin
OT  - respiratory tract infections
EDAT- 2011/06/16 06:00
MHDA- 2011/06/16 06:01
PMCR- 2011/04/18
CRDT- 2011/06/16 06:00
PHST- 2011/04/15 00:00 [received]
PHST- 2011/06/16 06:00 [entrez]
PHST- 2011/06/16 06:00 [pubmed]
PHST- 2011/06/16 06:01 [medline]
PHST- 2011/04/18 00:00 [pmc-release]
AID - ijgm-4-317 [pii]
AID - 10.2147/IJGM.S14537 [doi]
PST - ppublish
SO  - Int J Gen Med. 2011;4:317-23. doi: 10.2147/IJGM.S14537. Epub 2011 Apr 18.